Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0WCYUM
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Lupartumab amadotin
|
|||||
| Synonyms |
BAY 1129980; BAY-1129980; Anti-C4.4a antibody-drug conjugates; Anti-LY6-PLAUR domain containing 3 antibody-drug conjugates; Anti-LYPD3 antibody-drug conjugates; LYPD3 protein-directed antibody-drug conjugates
Click to Show/Hide
|
|||||
| Organization |
Bayer AG
|
|||||
| Drug Status |
Phase 1
|
|||||
| Indication |
In total 1 Indication(s)
Solid tumors [ICD11:2A00-2A0Z|2B50-2F9Z]
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
| Antibody Name |
Lupartumab
|
Antibody Info | ||||
| Antigen Name |
Ly6/PLAUR domain-containing protein 3 (LYPD3)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Linker Name |
Undisclosed
|
|||||
| Puchem SID | ||||||
| TTD ID | ||||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.